Depressive-like behaviour of mice lacking cellular prion protein

Behavioural Brain Research

Volumn 227, Issue 2, 2012, Pages 319-323

  Gadotti, Vinicius M ^a   Bonfield, Stephan P ^a   Zamponi, Gerald W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Depression; Forced swimming test; Knockout mice; Nmda receptor; Prion protein; Tail suspension test

Indexed keywords

CELLULAR PRION PROTEIN; DIZOCILPINE; IMIPRAMINE; PRION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; EXPERIMENTAL TEST; FORCED SWIMMING TEST; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TAIL SUSPENSION TEST; WILD TYPE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; IMIPRAMINE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PRPC PROTEINS; SWIMMING;

EID: 84855954078     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.03.012     Document Type: Article

References (37)

1. Appleby B.S. Psychotropic medications and the treatment of human prion diseases. CNS Neurol Disord Drug Targets 2009, 8:353-362.
2. Bhatnagar S., Nowak N., Babich L., Bok L. Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav Brain Res 2004, 153:527-535.
3. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 1995, 19:377-395.
4. Budni J., Gadotti V.M., Kaster M.P., Santos A.R., Rodrigues A.L. Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. Eur J Pharmacol 2007, 575:87-93.
5. Bueler H., Fischer M., Lang Y., Bluethmann H., Lipp H.P., DeArmond S.J., et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992, 356:577-582.
6. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161:598-607.
7. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 2003, 54:49-58.
8. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
9. Cumbler E., Furfari K., Guerrasio J. Creutzfeldt-Jakob disease presenting as severe depression: a case report. Cases J 2009, 2:122.
10. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
11. El Yacoubi M., Ledent C., Parmentier M., Bertorelli R., Ongini E., Costentin J., et al. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology A2A receptor knockout mice. Br J Pharmacol 2001, 134:68-77.
12. Jardri R., DiPaola C., Lajugie C., Thomas P., Goeb J.L. Depressive disorder with psychotic symptoms as psychiatric presentation of sporadic Creutzfeldt-Jakob disease: a case report. Gen Hosp Psychiatry 2006, 28:452-454.
13. Jiang T.T., Moses H., Gordon H., Obah E. Sporadic Creutzfeldt-Jakob disease presenting as major depression. South Med J 1999, 92:807-808.
14. Joca S.R., Ferreira F.R., Guimarães F.S. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 2007, 10:227-249.
15. Khosravani H., Zhang Y., Tsutsui S., Hameed S., Altier C., Hamid J., et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Cell Biol 2008, 181:551-565.
16. Klingenstein R., Löber S., Kujala P., Godsave S., Leliveld S.R., Gmeiner P., et al. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J. Neurochem 2006, 98:748-759.
17. Kos T., Legutko B., Danysz W., Samoriski G., Popik P. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. J Pharmacol Exp Ther 2006, 318:1128-1136.
18. Lobão-Soares B., Walz R., Carlotti C.G., Sakamoto A.C., Calvo F., Terzian A.L., et al. Cellular prion protein regulates the motor behaviour performance and anxiety-induced responses in genetically modified mice. Behav Brain Res 2007, 183:87-94.
19. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009, 123:143-150.
20. Macqueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 2011, 16:252-264.
21. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007, 9:467-474.
22. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
23. Murray C.J., Lopez A.D. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
24. Murray C.J., Lopez A.D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996, 274:740-743.
25. Nico P.B., de-Paris F., Vinadé E.R., Amaral O.B., Rockenbach I., Soares B.L., et al. Altered behavioural response to acute stress in mice lacking cellular prion protein. Behav Brain Res 2005, 162:173-181.
26. O'Reilly K.C., Shumake J., Gonzalez-Lima F., Lane M.A., Bailey S.J. Chronic administration of 13-cis-retinoic acid increases depression-related behavior in mice. Neuropsychopharmacology 2006, 31:1919-1927.
27. Ozawa S., Kamiya H., Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998, 54:581-618.
28. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
29. Réus G.Z., Stringari R.B., Kirsch T.R., Fries G.R., Kapczinski F., Roesler R., et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression?. Brain Res Bull 2010, 81:585-589.
30. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
31. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
32. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
33. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004, 161:1957-1966.
34. Wall C.A., Rummans T.A., Aksamit A.J., Krahn L.E., Pankratz V.S. Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25-year analysis. J Neuropsychiatry Clin Neurosci 2005, 17:489-495.
35. Weis S., Haybaeck J., Dulay J.R., Llenos I.C. Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression. J Neural Transm 2008, 115:761-771.
36. Wong D.T., Bymaster F.P. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants-potential for greater efficacy or just hype?. Prog Drug Res 2002, 58:169-222.
37. Zamponi G.W., Stys P.K. Role of prions in neuroprotection and neurodegeneration: a mechanism involving glutamate receptors?. Prion 2009, 3:187-189.